Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis: A prospective, randomized, double-blind, placebo-controlled clinical study

British Journal of Dermatology

Volumn 159, Issue 6, 2008, Pages 1357-1363

  Gueniche, A ^a   Knaudt, B ^b   Schuck, E ^b   Volz, T ^b   Bastien, P ^a   Martin, R ^a   Rocken M ^b   Breton, L ^a   Biedermann, T ^b  

^a L ORÉAL RECHERCHE   (France)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Atopic dermatitis; Bacterial lysate; Pruritus; Vitreoscilla filiformis

Indexed keywords

BACTERIUM LYSATE; PLACEBO; PROBIOTIC AGENT; UNCLASSIFIED DRUG; VITREOSCILLA FILIFORMIS EXTRACT;

ADOLESCENT; ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; BACTERIAL COLONIZATION; BACTERIAL IMMUNITY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GRAM NEGATIVE BACTERIUM; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SKIN FLORA; SKIN PROTECTION; SKIN WATER LOSS; SLEEP DISORDER; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME; VITREOSCILLA FILIFORMIS;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; BIOLOGICAL PRODUCTS; CHILD; DERMATITIS, ATOPIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS; VITREOSCILLA; YOUNG ADULT;

EID: 56549098062     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08836.x     Document Type: Article

References (45)

1. Leung DY, Boguniewicz M, Howell MD et al. New insights into atopic dermatitis. J Clin Invest 2004 113 : 651 7.
2. Leung DY, Bieber T. Atopic dermatitis. Lancet 2003 361 : 151 60.
3. Biedermann T. Dissecting the role of infections in atopic dermatitis. Acta Derm Venereol 2006 86 : 99 109.
4. Wittmann M, Werfel T. Interaction of keratinocytes with infiltrating lymphocytes in allergic eczematous skin diseases. Curr Opin Allergy Clin Immunol 2006 6 : 329 34.
5. Morar N, Willis-Owen SA, Moffatt MF et al. The genetics of atopic dermatitis. J Allergy Clin Immunol 2006 118 : 24 34.
6. Hudson TJ. Skin barrier function and allergic risk. Nat Genet 2006 38 : 399 400.
7. Palmer CN, Irvine AD, Terron-Kwiatkowski A et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006 38 : 441 6.
8. Weidinger S, Illig T, Baurecht H et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol 2006 118 : 214 19.
9. Irvine AD. Fleshing out filaggrin phenotypes. J Invest Dermatol 2007 127 : 504 7.
10. Uehara M, Miyauchi H. The morphologic characteristics of dry skin in atopic dermatitis. Arch Dermatol 1984 120 : 1186 90.
11. Biedermann T, Schwärzler C, Lametschwandtner G et al. Targeting CLA/E-selectin interactions prevents CCR4-mediated recruitment of human Th2 memory cells to human skin in vivo. Eur J Immunol 2002 32 : 3171 80.
12. Sager N, Feldmann A, Schilling G et al. House dust mite-specific T cells in the skin of subjects with atopic dermatitis: frequency and lymphokine profile in the allergen patch test. J Allergy Clin Immunol 1992 89 : 801 10.
13. Hamid Q, Boguniewicz M, Leung DY. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 1994 94 : 870 6.
14. Biedermann T, Röcken M, Carballido JM. TH1 and TH2 lymphocyte development and regulation of TH cell-mediated immune responses of the skin. J Investig Dermatol Symp Proc 2004 9 : 5 14.
15. Biedermann T, Röcken M. Th1/Th2 balance in atopy. Springer Semin Immunopathol 1999 21 : 295 316.
16. Kondo H, Ichikawa Y, Imokawa G. Percutaneous sensitization with allergens through barrier-disrupted skin elicits a Th2-dominant cytokine response. Eur J Immunol 1998 28 : 769 79.
17. Cork MJ, Robinson DA, Vasilopoulos Y et al. New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. J Allergy Clin Immunol 2006 118 : 3 21.
18. Biedermann T, Zimmermann S, Himmelrich H et al. IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice. Nat Immunol 2001 2 : 1054 60.
19. Ong PY, Ohtake T, Brandt C et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002 347 : 1151 60.
20. Howell MD, Gallo RL, Boguniewicz M et al. Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity 2006 24 : 341 8.
21. Rieg S, Steffen H, Seeber S et al. Deficiency of dermcidin-derived antimicrobial peptides in sweat of patients with atopic dermatitis correlates with an impaired innate defense of human skin in vivo. J Immunol 2005 174 : 8003 10.
22. Ong PY, Leung DY. Immune dysregulation in atopic dermatitis. Curr Allergy Asthma Rep 2006 6 : 384 9.
23. Roll A, Cozzio A, Fischer B et al. Microbial colonization and atopic dermatitis. Curr Opin Allergy Clin Immunol 2004 4 : 373 8.
24. Cho SH, Strickland I, Tomkinson A et al. Preferential binding of Staphylococcus aureus to skin sites of Th2-mediated inflammation in a murine model. J Invest Dermatol 2001 116 : 658 63.
25. Hauser C, Wilhelm JA, Matter L et al. Spontaneous and pokeweed mitogen-induced in vitro IgG production specific for S. aureus cell wall determinants in man. Clin Exp Immunol 1984 57 : 227 33.
26. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004 118 : 229 41.
27. Rakoff-Nahoum S, Medzhitov R. Role of the innate immune system and host-commensal mutualism. Curr Top Microbiol Immunol 2006 308 : 1 18.
28. Higaki S, Morohashi M, Yamagishi T et al. Comparative study of staphylococci from the skin of atopic dermatitis patients and from healthy subjects. Int J Dermatol 1999 38 : 265 9.
29. Holt JG (ed Bergey's Manual of Determinative Bacteriology, 9th edn. Baltimore : Lippincott Williams & Wilkins, 1994.
30. Gueniche A, Hennino A, Goujon C et al. Improvement of atopic dermatitis skin symptoms by Vitreoscilla filiformis bacterial extract. Eur J Dermatol 2006 16 : 380 4.
31. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockholm) 1980 92 : 44 7.
32. Kunz B, Oranje AP, Labreze L et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997 195 : 10 19.
33. Oranje AP, Glazenburg EJ, Wolkerstorfer A et al. Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score. Br J Dermatol 2007 157 : 645 8.
34. Williamson P, Kligman AM. A new method for the quantitative investigation of cutaneous bacteria. J Invest Dermatol 1965 45 : 498 503.
35. Guzik TJ, Bzowska M, Kasprowicz A et al. Persistent skin colonization with Staphylococcus aureus in atopic dermatitis: relationship to clinical and immunological parameters. Clin Exp Allergy 2005 35 : 448 55.
36. Cogen AL, Nizet V, Gallo RL. Skin microbiota: a source of disease or defence? Br J Dermatol 2008 158 : 442 55.
37. Kukkonen K, Savilahti E, Haahtela T et al. Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2007 119 : 192 8.
38. Kalliomaki M, Salminen S, Arvilommi H et al. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001 357 : 1076 9.
39. Weston S, Halbert A, Richmond P et al. Effects of probiotics on atopic dermatitis: a randomised controlled trial. Arch Dis Child 2005 90 : 892 7.
40. Grüber C, Wendt M, Sulser C et al. Randomized, placebo-controlled trial of Lactobacillus rhamnosus GG as treatment of atopic dermatitis in infancy. Allergy 2007 62 : 1270 6.
41. Taylor AL, Dunstan JA, Prescott SL. Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: a randomized controlled trial. J Allergy Clin Immunol 2007 119 : 184 91.
42. Folster-Hölst R, Muller F, Schnopp N et al. Prospective, randomized controlled trial on Lactobacillus rhamnosus in infants with moderate to severe atopic dermatitis. Br J Dermatol 2006 155 : 1256 61.
43. Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics 2005 115 : 5 9.
44. Moro G, Arslanoglu S, Stahl B et al. A mixture of prebiotic oligosaccharides reduces the incidence of atopic dermatitis during the first six months of age. Arch Dis Child 2006 91 : 814 19.
45. Sistek D, Kelly R, Wickens K et al. Is the effect of probiotics on atopic dermatitis confined to food sensitized children? Clin Exp Allergy 2006 36 : 629 33.